223 related articles for article (PubMed ID: 34473252)
1. Flow cytometry allows rapid detection of protein aggregates in cellular and zebrafish models of spinocerebellar ataxia 3.
Robinson KJ; Tym MC; Hogan A; Watchon M; Yuan KC; Plenderleith SK; Don EK; Laird AS
Dis Model Mech; 2021 Oct; 14(10):. PubMed ID: 34473252
[TBL] [Abstract][Full Text] [Related]
2. Treatment with sodium butyrate induces autophagy resulting in therapeutic benefits for spinocerebellar ataxia type 3.
Watchon M; Robinson KJ; Luu L; An Y; Yuan KC; Plenderleith SK; Cheng F; Don EK; Nicholson GA; Lee A; Laird AS
FASEB J; 2024 Jan; 38(2):e23429. PubMed ID: 38258931
[TBL] [Abstract][Full Text] [Related]
3. A Novel Calpain Inhibitor Compound Has Protective Effects on a Zebrafish Model of Spinocerebellar Ataxia Type 3.
Robinson KJ; Yuan K; Plenderleith SK; Watchon M; Laird AS
Cells; 2021 Sep; 10(10):. PubMed ID: 34685571
[TBL] [Abstract][Full Text] [Related]
4. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3.
Chen ZS; Huang X; Talbot K; Chan HYE
Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212
[TBL] [Abstract][Full Text] [Related]
5. Calpain Inhibition Is Protective in Machado-Joseph Disease Zebrafish Due to Induction of Autophagy.
Watchon M; Yuan KC; Mackovski N; Svahn AJ; Cole NJ; Goldsbury C; Rinkwitz S; Becker TS; Nicholson GA; Laird AS
J Neurosci; 2017 Aug; 37(32):7782-7794. PubMed ID: 28687604
[TBL] [Abstract][Full Text] [Related]
6. Autophagy Function and Benefits of Autophagy Induction in Models of Spinocerebellar Ataxia Type 3.
Watchon M; Luu L; Plenderleith SK; Yuan KC; Laird AS
Cells; 2023 Mar; 12(6):. PubMed ID: 36980234
[TBL] [Abstract][Full Text] [Related]
7. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
8. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
Li X; Liu H; Fischhaber PL; Tang TS
Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease.
Nascimento-Ferreira I; Santos-Ferreira T; Sousa-Ferreira L; Auregan G; Onofre I; Alves S; Dufour N; Colomer Gould VF; Koeppen A; Déglon N; Pereira de Almeida L
Brain; 2011 May; 134(Pt 5):1400-15. PubMed ID: 21478185
[TBL] [Abstract][Full Text] [Related]
10. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiological interplay between
Pereira Sena P; Weber JJ; Watchon M; Robinson KJ; Wassouf Z; Hauser S; Helm J; Abeditashi M; Schmidt J; Hübener-Schmid J; Schöls L; Laird AS; Riess O; Schmidt T
Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34785590
[TBL] [Abstract][Full Text] [Related]
12. Vulnerability of frontal brain neurons for the toxicity of expanded ataxin-3.
Schmidt J; Mayer AK; Bakula D; Freude J; Weber JJ; Weiss A; Riess O; Schmidt T
Hum Mol Genet; 2019 May; 28(9):1463-1473. PubMed ID: 30576445
[TBL] [Abstract][Full Text] [Related]
13. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
[TBL] [Abstract][Full Text] [Related]
14. Sodium valproate increases activity of the sirtuin pathway resulting in beneficial effects for spinocerebellar ataxia-3 in vivo.
Watchon M; Luu L; Robinson KJ; Yuan KC; De Luca A; Suddull HJ; Tym MC; Guillemin GJ; Cole NJ; Nicholson GA; Chung RS; Lee A; Laird AS
Mol Brain; 2021 Aug; 14(1):128. PubMed ID: 34416891
[TBL] [Abstract][Full Text] [Related]
15. Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease.
Ashraf NS; Duarte-Silva S; Shaw ED; Maciel P; Paulson HL; Teixeira-Castro A; Costa MDC
Mol Neurobiol; 2019 May; 56(5):3690-3701. PubMed ID: 30187384
[TBL] [Abstract][Full Text] [Related]
16.
Lee JH; Lin SY; Liu JW; Lin SZ; Harn HJ; Chiou TW
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199295
[TBL] [Abstract][Full Text] [Related]
17. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease.
Koch P; Breuer P; Peitz M; Jungverdorben J; Kesavan J; Poppe D; Doerr J; Ladewig J; Mertens J; Tüting T; Hoffmann P; Klockgether T; Evert BO; Wüllner U; Brüstle O
Nature; 2011 Nov; 480(7378):543-6. PubMed ID: 22113611
[TBL] [Abstract][Full Text] [Related]
18. Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.
Raj K; Akundi RS
Mol Neurobiol; 2021 Jul; 58(7):3095-3118. PubMed ID: 33629274
[TBL] [Abstract][Full Text] [Related]
19. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL
Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
[TBL] [Abstract][Full Text] [Related]
20. FipoQ/FBXO33, a Cullin-1-based ubiquitin ligase complex component modulates ubiquitination and solubility of polyglutamine disease protein.
Chen ZS; Wong AKY; Cheng TC; Koon AC; Chan HYE
J Neurochem; 2019 Jun; 149(6):781-798. PubMed ID: 30685895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
